TLV •
Healthcare •
Biotechnology •
Quote as of 07/29/2026 17:24
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTLV
Market Capitalization499.71 mln
Float31.59 mln
Earnings Date08/14/2026
EPS
7.76
Strong
P / E
1.57
Deeply undervalued
Piotroski F-Score
2
/ 9
Weak
Relative Strength
85
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
58.72
Exceptional
Business Description
Oramed Pharmaceuticals is a drug development company focused on creating pills that deliver proteins and insulin directly through the digestive system, removing the need for injections. Its lead product, an oral insulin capsule, has advanced to late-stage clinical trials for people living with diabetes. The company also holds licensing rights to develop oral COVID-19 vaccines through a partnership with Oravax Medical. Founded in 2002 and based in New York, Oramed aims to make treatment easier and more accessible for patients worldwide.
